0
     

Report Added
Report already added
Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027

Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027

The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% during the forecast period. The growth of the market is projected to be driven by collaborations and agreements among market players for stem cell assay products & services, launch of new stem cell analysis systems such as flow cytometers and increase in R&D expenditure by biopharmaceutical and biotechnology companies.

The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021.

Cell viability assays help to determine the number of live and dead cells in a culture medium. The viability/cytotoxicity assays includes various types such as tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, and other viability/cytotoxicity assays. The cell viability/cytotoxicity market is likely to be driven by rise R&D spending on stem cell research, increase in demand for stem cell assays in drug discovery and development of new stem cell therapies..

The adult stem cells segment accounted for the largest share of the cell type segment in the stem cell assays market in 2021.

The adult stem cells account for the largest share of the stem cell assays market. The adult stem cells include mesenchymal stem cells, induced pluripotent stem cells, hematopoietic stem cells, umbilical cord stem cells, and neural stem cells. The growth of adult stems cells segment is driven by increasing usage of adult stem cells in regenerative medicine and development of advanced therapies.

Key players in the stem cell assays market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), PerkinElmer (US), Agilent Technologies (US), Promega Corporation (US), Cell Biolabs (US), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Bio-Techne Corporation (US), FUJIFILM Holdings Corporation (Japan), Charles River Laboratories (US), HemoGenix Inc. (US), Lonza Group (Switzerland), Takara Bio Inc. (Japan), Creative Bioarray (US), AAT Bioquest, Inc. (US), BPS Bioscience, Inc. (US), Enzo Biochem (US), PromoCell GmbH (Germany), Biotium (US), Geno Technology (US), Abcam plc (UK), and ReachBio Research Labs (US).

“Asia Pacific: The fastest-growing region in the stem cell assays market”

The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to rising prevalence of cancer & other diseases, increasing R&D spending on biopharmaceutical projects and focus on developing stem cell based therapies. In this region, China and Japan are the largest markets.

The primary interviews conducted for this report can be categorized as follows:
•By Respondent: Supply Side- 80% and Demand Side - 20%
•By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
•By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:
•Thermo Fisher Scientific Inc. (US)
•Merck KGaA (Germany)
•Danaher (US)
•Becton, Dickinson and Company (US)
•Bio-Rad Laboratories (US)
•PerkinElmer (US)
•Agilent Technologies (US)
•Promega Corporation (US)
•Cell Biolabs (US)
•Miltenyi Biotec (Germany)
•STEMCELL Technologies (Canada)
•Bio-Techne Corporation (US)
•FUJIFILM Holdings Corporation (Japan)
•Charles River Laboratories (US)
•HemoGenix Inc. (US)
•Lonza Group (Switzerland)
•Takara Bio Inc. (Japan)
•Creative Bioarray (US)
•AAT Bioquest, Inc. (US)
•BPS Bioscience, Inc. (US)
•Enzo Biochem (US)
•PromoCell GmbH (Germany)
•Biotium (US)
•Geno Technology (US)
•Abcam plc (UK)
•ReachBio Research Labs (US).

Research Coverage:
This report provides a detailed picture of the stem cell assays market. It aims at estimating the size and future growth potential of the market across different segments such as the product, functionality, formulation and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.
Table of Contents

1INTRODUCTION47
1.1OBJECTIVES OF THE STUDY47
1.2MARKET DEFINITION47
1.2.1INCLUSIONS & EXCLUSIONS48
1.3MARKET SCOPE49
1.3.1MARKETS COVERED49
1.3.2YEARS CONSIDERED FOR THE STUDY50
1.4CURRENCY50
1.5LIMITATIONS50
1.6STAKEHOLDERS51
1.7SUMMARY OF CHANGES51
2RESEARCH METHODOLOGY53
2.1RESEARCH DATA53
FIGURE 1RESEARCH DESIGN53
2.1.1SECONDARY DATA54
2.1.2PRIMARY DATA55
FIGURE 2BREAKDOWN OF PRIMARIES, BY RESPONDENT, DESIGNATION, AND REGION55
2.2MARKET ESTIMATION METHODOLOGY56
FIGURE 3STEM CELL ASSAYS MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 202156
FIGURE 4MARKET SIZE ESTIMATION: APPROACH 1
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 202157
2.2.1INSIGHTS FROM PRIMARY EXPERTS58
FIGURE 5MARKET SIZE VALIDATION FROM PRIMARY SOURCES58
2.3MARKET GROWTH RATE PROJECTIONS59
FIGURE 6STEM CELL ASSAYS MARKET (SUPPLY SIDE): CAGR PROJECTIONS60
FIGURE 7STEM CELL ASSAYS MARKET (DEMAND SIDE):
GROWTH ANALYSIS OF DEMAND-SIDE FACTORS61
2.3.1DATA TRIANGULATION62
FIGURE 8DATA TRIANGULATION METHODOLOGY62
2.4RESEARCH ASSUMPTIONS63
2.4.1COVID-19 ASSUMPTIONS63
2.5RISK ANALYSIS64
3EXECUTIVE SUMMARY65
FIGURE 9STEM CELL ASSAYS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)65
FIGURE 10STEM CELL ASSAYS MARKET, BY CELL TYPE, 2022 VS. 2027 (USD MILLION)66
FIGURE 11STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2022 VS. 2027 (USD MILLION)66
FIGURE 12STEM CELL ASSAYS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION)67
FIGURE 13STEM CELL ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)68
FIGURE 14GEOGRAPHICAL SNAPSHOT OF STEM CELL ASSAYS MARKET69
4PREMIUM INSIGHTS70
4.1STEM CELL ASSAYS MARKET OVERVIEW70
FIGURE 15RISING AWARENESS ABOUT THERAPEUTIC POTENCY OF
STEM CELLS TO DRIVE MARKET GROWTH70
4.2NORTH AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2021)71
FIGURE 16INSTRUMENTS SEGMENT ACCOUNTED FOR
LARGEST MARKET SHARE IN 202171
4.3STEM CELL ASSAYS MARKET SHARE, BY TYPE, 2022 VS. 202771
FIGURE 17VIABILITY/CYTOTOXICITY ASSAYS SEGMENT WILL CONTINUE
TO DOMINATE MARKET IN 202771
4.4STEM CELL ASSAYS MARKET SHARE, BY APPLICATION, 202172
FIGURE 18REGENERATIVE MEDICINE & THERAPY DEVELOPMENT SEGMENT
DOMINATED MARKET IN 202172
4.5STEM CELL ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES73
FIGURE 19ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE
FROM 2022 TO 202773
5MARKET OVERVIEW74
5.1INTRODUCTION74
5.2MARKET DYNAMICS74
FIGURE 20STEM CELL ASSAYS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES74
TABLE 1STEM CELL ASSAYS MARKET: IMPACT ANALYSIS75
5.2.1DRIVERS75
5.2.1.1Increasing awareness about therapeutic potency of stem cells75
5.2.1.2Increasing funding for stem cell research76
5.2.1.3Rising demand for cell-based assays in drug discovery77
5.2.1.4Collaborations and agreements among market players for stem cell assay products & services77
5.2.1.5Rising incidence of cancer78
TABLE 2GLOBAL CANCER INCIDENCE, 2020 VS. 204078
5.2.2RESTRAINTS78
5.2.2.1Issues in embryonic stem cell research78
5.2.2.2High cost of stem cell analysis instruments78
5.2.3OPPORTUNITIES79
5.2.3.1Emerging economies79
5.2.3.2Government initiatives to boost stem cell research79

5.2.4CHALLENGES80
5.2.4.1Lack of infrastructure for stem cell research in emerging economies80
5.2.4.2Dearth of trained and skilled professionals80
5.3RANGES/SCENARIOS81
FIGURE 21SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF STEM CELL ASSAYS MARKET81
5.4IMPACT OF COVID-19 ON STEM CELL ASSAYS MARKET81
5.4.1INTRODUCTION81
5.4.2RESEARCH & DEVELOPMENT82
5.4.3RESEARCH FUNDING82
5.4.4SUPPLY CHAIN82
FIGURE 22STEM CELL ASSAYS MARKET SCENARIO WITH AND WITHOUT
COVID-19 IMPACT, 2019-202183
5.5TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS84
FIGURE 23REVENUE SHIFT AND NEW REVENUE POCKETS FOR
STEM CELL ASSAY PRODUCT PROVIDERS84
5.6PRICING ANALYSIS84
5.6.1AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS84
TABLE 3AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (TOP 5)84
5.6.2AVERAGE SELLING PRICE TREND85
5.7TECHNOLOGY ANALYSIS85
5.7.1MICROFABRICATION-ASSISTED TECHNOLOGIES85
5.7.1.1Microfluidics-based cell trap technology85
5.7.1.2Droplet-based microfluidic technology86
5.7.1.3Microwell-based analysis systems86
5.7.2ADVANCED TECHNOLOGIES86
5.7.2.1Bead-based multiplex assays86
5.8VALUE CHAIN ANALYSIS86
FIGURE 24VALUE CHAIN ANALYSIS OF STEM CELL ASSAYS MARKET87
5.9SUPPLY CHAIN ANALYSIS88
FIGURE 25STEM CELL ASSAYS MARKET: SUPPLY CHAIN ANALYSIS89
5.10ECOSYSTEM ANALYSIS89
FIGURE 26ECOSYSTEM ANALYSIS: STEM CELL ASSAYS MARKET89
TABLE 4SUPPLY CHAIN ECOSYSTEM90
5.11PATENT ANALYSIS91
FIGURE 27PATENT APPLICATIONS RELATED TO STEM CELL ASSAYS MARKET,
JANUARY 2012–MARCH 202291
5.12KEY CONFERENCES AND EVENTS IN 2022–202392
TABLE 5STEM CELL ASSAYS MARKET: LIST OF CONFERENCES AND EVENTS92
5.13REGULATORY ANALYSIS94
5.13.1LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES94
5.13.2REGULATORY ANALYSIS FOR STEM CELL RESEARCH95
5.13.2.1US95
5.13.2.2EUROPE95
5.13.2.2.1Germany95
5.13.2.2.2UK95
5.13.2.2.3France95
5.13.2.2.4Italy95
5.13.2.2.5Spain96
5.13.2.2.6Switzerland96
5.13.3REGULATORY ANALYSIS FOR STEM CELL THERAPY96
5.13.3.1US96
5.13.3.2European Union97
5.14PORTER’S FIVE FORCES ANALYSIS97
TABLE 6STEM CELL ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS97
5.14.1THREAT OF NEW ENTRANTS98
5.14.2THREAT OF SUBSTITUTES98
5.14.3BARGAINING POWER OF BUYERS98
5.14.4BARGAINING POWER OF SUPPLIERS98
5.14.5DEGREE OF COMPETITION98
5.15KEY STAKEHOLDERS AND BUYING CRITERIA99
5.15.1KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES
AND THEIR INFLUENCE IN BUYING PROCESS99
FIGURE 28INFLUENCE OF STAKEHOLDERS IN PHARMACEUTICAL
COMPANIES IN BUYING PROCESS OF STEM CELL ASSAY PRODUCTS99
5.15.2KEY BUYING CRITERIA FOR STEM CELL ASSAY PRODUCTS
AMONG END USERS99
FIGURE 29KEY BUYING CRITERIA FOR END USERS99
6STEM CELL ASSAYS MARKET, BY TYPE100
6.1INTRODUCTION101
TABLE 7STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)101
6.2VIABILITY/CYTOTOXICITY ASSAYS101
TABLE 8VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)102
TABLE 9NORTH AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)102
TABLE 10EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)102
TABLE 11ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)103
TABLE 12VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION)103
6.2.1TETRAZOLIUM REDUCTION ASSAYS103
6.2.1.1Growing use of tetrazolium reduction assays in high-throughput screening to drive segment growth103
TABLE 13TETRAZOLIUM REDUCTION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)104
TABLE 14NORTH AMERICA: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)104
TABLE 15EUROPE: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)104
TABLE 16ASIA PACIFIC: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)105
6.2.2RESAZURIN CELL VIABILITY ASSAYS105
6.2.2.1Several advantages of resazurin cell viability assays to increase their adoption105
TABLE 17RESAZURIN CELL VIABILITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)105
TABLE 18NORTH AMERICA: RESAZURIN CELL VIABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)106
TABLE 19EUROPE: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)106
TABLE 20ASIA PACIFIC: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)106
6.2.3CALCEIN-AM CELL VIABILITY ASSAYS107
6.2.3.1Wide applications of Calcein-AM cell viability assays across various assay techniques to drive segment growth107
TABLE 21CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)107
TABLE 22NORTH AMERICA: CALCEIN-AM CELL VIABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)107
TABLE 23EUROPE: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)108
TABLE 24ASIA PACIFIC: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)108
6.2.4OTHER VIABILITY/CYTOTOXICITY ASSAYS108
TABLE 25OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)109
TABLE 26NORTH AMERICA: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)109
TABLE 27EUROPE: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)109
TABLE 28ASIA PACIFIC: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)110
6.3ISOLATION & PURIFICATION ASSAYS110
6.3.1GROWING USE OF ISOLATION & PURIFICATION IN STEM CELL
ANALYSIS TO DRIVE SEGMENT GROWTH110
TABLE 29ISOLATION & PURIFICATION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)110
TABLE 30NORTH AMERICA: ISOLATION & PURIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)111
TABLE 31EUROPE: ISOLATION & PURIFICATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)111
TABLE 32ASIA PACIFIC: ISOLATION & PURIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)111
6.4CELL IDENTIFICATION ASSAYS112
6.4.1CELL IDENTIFICATION ASSAYS IDENTIFY TARGET CELLS THROUGH MARKERS, BUFFERS, AND REAGENTS112
TABLE 33CELL IDENTIFICATION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)112
TABLE 34NORTH AMERICA: CELL IDENTIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)112
TABLE 35EUROPE: CELL IDENTIFICATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)113
TABLE 36ASIA PACIFIC: CELL IDENTIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)113
6.5PROLIFERATION ASSAYS114
6.5.1CELL PROLIFERATION IS MEASURED ON THE BASIS OF
AVERAGE DNA CONTENT AND CELLULAR METABOLISM114
TABLE 37PROLIFERATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)114
TABLE 38NORTH AMERICA: PROLIFERATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)114
TABLE 39EUROPE: PROLIFERATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)115
TABLE 40ASIA PACIFIC: PROLIFERATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)115
6.6DIFFERENTIATION ASSAYS116
6.6.1AVAILABILITY OF VARIOUS STEM CELL DIFFERENTIAL ASSAY KITS TO BOOST SEGMENT GROWTH116
TABLE 41DIFFERENTIATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)116
TABLE 42NORTH AMERICA: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)116
TABLE 43EUROPE: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)117
TABLE 44ASIA PACIFIC: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)117
6.7FUNCTION ASSAYS118
6.7.1RISING DEMAND FOR FUNCTION ASSAYS IN DRUG DISCOVERY TO DRIVE SEGMENT GROWTH118
TABLE 45FUNCTION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)118
TABLE 46NORTH AMERICA: FUNCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)118
TABLE 47EUROPE: FUNCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)119
TABLE 48ASIA PACIFIC: FUNCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)119
6.8APOPTOSIS ASSAYS120
TABLE 49APOPTOSIS ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)120
TABLE 50NORTH AMERICA: APOPTOSIS ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)120
TABLE 51EUROPE: APOPTOSIS ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)121
TABLE 52ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)121
TABLE 53APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)121
6.8.1CASPASE ASSAYS122
6.8.1.1Advantages offered by caspase assays to drive segment growth122
TABLE 54CASPASE ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)122
TABLE 55NORTH AMERICA: CASPASE ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)122
TABLE 56EUROPE: CASPASE ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)123
TABLE 57ASIA PACIFIC: CASPASE ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)123
6.8.2ANNEXIN V & CELL PERMEABILITY ASSAYS123
6.8.2.1Increasing use of annexin V and cell permeability assays to drive segment growth123
TABLE 58ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)124
TABLE 59NORTH AMERICA: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)124
TABLE 60EUROPE: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)124
TABLE 61ASIA PACIFIC: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)125
6.8.3DNA FRAGMENTATION ASSAYS125
6.8.3.1DNA fragmentation assays are used to study the
later stages of apoptosis125
TABLE 62DNA FRAGMENTATION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)125
TABLE 63NORTH AMERICA: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)126
TABLE 64EUROPE: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)126
TABLE 65ASIA PACIFIC: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)126
6.8.4MITOCHONDRIAL ASSAYS127
6.8.4.1Mitochondrial assays are widely used to detect mitochondrial changes associated with apoptosis127
TABLE 66MITOCHONDRIAL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)127
TABLE 67NORTH AMERICA: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)127
TABLE 68EUROPE: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)128
TABLE 69ASIA PACIFIC: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)128

7STEM CELL ASSAYS MARKET, BY CELL TYPE129
7.1INTRODUCTION130
TABLE 70STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)130
7.2ADULT STEM CELLS130
TABLE 71ADULT STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)130
TABLE 72ADULT STEM CELLS ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)131
TABLE 73NORTH AMERICA: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)131
TABLE 74EUROPE: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)131
TABLE 75ASIA PACIFIC: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)132
7.2.1MESENCHYMAL STEM CELLS132
7.2.1.1Increasing adoption of MSCs as potential treatment for various conditions to drive market growth132
TABLE 76MESENCHYMAL STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)133
TABLE 77NORTH AMERICA: MESENCHYMAL STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)133
TABLE 78EUROPE: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)134
TABLE 79ASIA PACIFIC: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)134
7.2.2INDUCED PLURIPOTENT STEM CELLS134
7.2.2.1Increased adoption of iPSCs in research on cell therapies & regenerative medicine to support market growth134
TABLE 80INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)135
TABLE 81NORTH AMERICA: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)135
TABLE 82EUROPE: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)136
TABLE 83ASIA PACIFIC: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)136
7.2.3HEMATOPOIETIC STEM CELLS136
7.2.3.1Increasing focus on developing HSC-based therapies to
drive market growth136
TABLE 84HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)137
TABLE 85NORTH AMERICA: HEMATOPOIETIC STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)137
TABLE 86EUROPE: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)138
TABLE 87ASIA PACIFIC: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)138
7.2.4UMBILICAL CORD STEM CELLS138
7.2.4.1Rising investments and collaborations for developing umbilical cord stem cell therapies to propel market growth138
TABLE 88UMBILICAL CORD STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)139
TABLE 89NORTH AMERICA: UMBILICAL CORD STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)139
TABLE 90EUROPE: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)140
TABLE 91ASIA PACIFIC: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)140
7.2.5NEURAL STEM CELLS140
7.2.5.1Increasing research to evaluate the potency of NSCs in disease treatment will drive segment growth140
TABLE 92NEURAL STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)141
TABLE 93NORTH AMERICA: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)141
TABLE 94EUROPE: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)142
TABLE 95ASIA PACIFIC: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)142
7.3HUMAN EMBRYONIC STEM CELLS142
7.3.1ESCS CAN BE STORED AND PROCESSED EASILY142
TABLE 96HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION)143
TABLE 97NORTH AMERICA: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)143
TABLE 98EUROPE: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)143
TABLE 99ASIA PACIFIC: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)144
8STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE145
8.1INTRODUCTION146
TABLE 100STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)146
8.2INSTRUMENTS146
TABLE 101STEM CELL ASSAY INSTRUMENTS MARKET, BY REGION,
2020–2027 (USD MILLION)147
TABLE 102NORTH AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)147
TABLE 103EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)147
TABLE 104ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)148
TABLE 105STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)148
8.2.1FLOW CYTOMETERS149
8.2.1.1Technological advancements in flow cytometry
to drive segment growth149
TABLE 106FLOW CYTOMETERS MARKET, BY REGION, 2020–2027 (USD MILLION)149
TABLE 107NORTH AMERICA: FLOW CYTOMETERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)150
TABLE 108EUROPE: FLOW CYTOMETERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)150
TABLE 109ASIA PACIFIC: FLOW CYTOMETERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)150
8.2.2CELL IMAGING & ANALYSIS SYSTEMS151
8.2.2.1High demand for cell imaging and analysis in cell behavior research studies to support segment growth151
TABLE 110CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY REGION,
2020–2027 (USD MILLION)151
TABLE 111NORTH AMERICA: CELL IMAGING & ANALYSIS SYSTEMS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)152
TABLE 112EUROPE: CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)152
TABLE 113ASIA PACIFIC: CELL IMAGING & ANALYSIS SYSTEMS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)152
8.2.3MICROELECTRODE ARRAYS153
8.2.3.1Increasing use of microelectrode arrays in stem cell research
to drive segment growth153
TABLE 114MICROELECTRODE ARRAYS MARKET, BY REGION, 2020–2027 (USD MILLION)153
TABLE 115NORTH AMERICA: MICROELECTRODE ARRAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)154
TABLE 116EUROPE: MICROELECTRODE ARRAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)154
TABLE 117ASIA PACIFIC: MICROELECTRODE ARRAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)154
8.2.4AUTOMATED CELL COUNTERS155
8.2.4.1Increasing adoption of automated cell counters to
drive segment growth155
TABLE 118AUTOMATED CELL COUNTERS MARKET, BY REGION,
2020–2027 (USD MILLION)155
TABLE 119NORTH AMERICA: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)155
TABLE 120EUROPE: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)156
TABLE 121ASIA PACIFIC: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)156
8.3KITS157
8.3.1RAPID EVOLUTION OF ASSAY PLATFORMS AND EMERGENCE OF NEW TECHNOLOGY PLATFORMS TO DRIVE SEGMENT GROWTH157
TABLE 122STEM CELL ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION)157
TABLE 123NORTH AMERICA: STEM CELL ASSAY KITS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)157
TABLE 124EUROPE: STEM CELL ASSAY KITS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)158
TABLE 125ASIA PACIFIC: STEM CELL ASSAY KITS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)158
8.4SERVICES159
8.4.1RISING DEMAND FOR ASSAY DEVELOPMENT SERVICES TO
DRIVE SEGMENT GROWTH159
TABLE 126STEM CELL ASSAY SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION)159
TABLE 127NORTH AMERICA: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)159
TABLE 128EUROPE: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)160
TABLE 129ASIA PACIFIC: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION)160
9STEM CELL ASSAYS MARKET, BY APPLICATION161
9.1INTRODUCTION162
TABLE 130STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)162
9.2REGENERATIVE MEDICINE & THERAPY DEVELOPMENT162
TABLE 131STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)163
TABLE 132NORTH AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY,
2020–2027 (USD MILLION)163
TABLE 133EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)163
TABLE 134ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)164
TABLE 135STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)164
9.2.1ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS164
9.2.1.1Increasing prevalence of orthopedic disorders to
drive segment growth164
TABLE 136STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)165
TABLE 137NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION)165
TABLE 138EUROPE: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION)166
TABLE 139ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION)166
9.2.2DERMATOLOGY APPLICATIONS167
9.2.2.1Increasing use of stem cells in skin disease treatment to drive segment growth167
TABLE 140STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION)167
TABLE 141NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)167
TABLE 142EUROPE: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)168
TABLE 143ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)168
9.2.3CARDIOVASCULAR APPLICATIONS169
9.2.3.1Growing demand for effective cardiovascular disease treatments and rising number of R&D activities to drive segment growth169
TABLE 144STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION)169
TABLE 145NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)170
TABLE 146EUROPE: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)170
TABLE 147ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)170
9.2.4CENTRAL NERVOUS SYSTEM APPLICATIONS171
9.2.4.1Promising stem cell therapies for degenerative neurological disorders to drive segment growth171
TABLE 148STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)171
TABLE 149NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)171
TABLE 150EUROPE: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)172
TABLE 151ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)172
9.2.5ONCOLOGY APPLICATIONS173
9.2.5.1Increasing prevalence of cancer to drive segment growth173
TABLE 152INCREASING INCIDENCE OF CANCER, BY REGION,
2020 VS. 2030 VS. 2040 (MILLION)173
TABLE 153PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015–2035173
TABLE 154STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION)174
TABLE 155NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)174
TABLE 156EUROPE: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION)174
TABLE 157ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)175
9.2.6DIABETES APPLICATIONS175
9.2.6.1Rising incidence of diabetes to drive segment growth175
TABLE 158TOP FIVE COUNTRIES WITH THE HIGHEST NUMBER OF
DIABETICS (20–79 YEARS), 2021 VS. 2045175
TABLE 159STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)176
TABLE 160NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)176
TABLE 161EUROPE: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION)177
TABLE 162ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION)177
9.2.7OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS178
TABLE 163STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY REGION,
2020–2027 (USD MILLION)178
TABLE 164NORTH AMERICA: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)178
TABLE 165EUROPE: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE
MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION)179
TABLE 166ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION)179
9.3DRUG DISCOVERY & DEVELOPMENT180
9.3.1RECENT PROGRESS IN THE DEVELOPMENT OF STEM CELL ASSAYS
TO DRIVE SEGMENT GROWTH180
TABLE 167STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT,
BY REGION, 2020–2027 (USD MILLION)180
TABLE 168NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)181
TABLE 169EUROPE: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)181
TABLE 170ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)181
9.4CLINICAL RESEARCH182
9.4.1INCREASING NUMBER OF PROMISING CLINICAL TRIALS USING
STEM CELLS TO BOOST SEGMENT GROWTH182
TABLE 171STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY REGION,
2020–2027 (USD MILLION)182
TABLE 172NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH,
BY COUNTRY, 2020–2027 (USD MILLION)182
TABLE 173EUROPE: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH,
BY COUNTRY, 2020–2027 (USD MILLION)183
TABLE 174ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH,
BY COUNTRY, 2020–2027 (USD MILLION)183

10STEM CELL ASSAYS MARKET, BY END USER184
10.1INTRODUCTION185
TABLE 175STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)185
10.2BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES185
10.2.1BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE LARGEST END USERS OF STEM CELL ASSAYS185
TABLE 176STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)186
TABLE 177NORTH AMERICA: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)186
TABLE 178EUROPE: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)187
TABLE 179ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)187
10.3ACADEMIC & RESEARCH INSTITUTES188
10.3.1NEW STEM CELL RESEARCH INSTITUTES ARE BEING ESTABLISHED FOR STEM CELL RESEARCH AND REGENERATIVE MEDICINE188
TABLE 180STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2020–2027 (USD MILLION)188
TABLE 181NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)189
TABLE 182EUROPE: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)189
TABLE 183ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)189
11STEM CELL ASSAYS MARKET, BY REGION190
11.1INTRODUCTION191
TABLE 184STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)191
11.2NORTH AMERICA191
FIGURE 30NORTH AMERICA: STEM CELL ASSAYS MARKET SNAPSHOT192
TABLE 185NORTH AMERICA: STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)193
TABLE 186NORTH AMERICA: STEM CELL ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION)193
TABLE 187NORTH AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION)193
TABLE 188NORTH AMERICA: APOPTOSIS ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION)194
TABLE 189NORTH AMERICA: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION)194
TABLE 190NORTH AMERICA: ADULT STEM CELLS MARKET, BY TYPE,
2020–2027 (USD MILLION)194
TABLE 191NORTH AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)195
TABLE 192NORTH AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)195
TABLE 193NORTH AMERICA: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)195
TABLE 194NORTH AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)196
TABLE 195NORTH AMERICA: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION)196
11.2.1US196
11.2.1.1Rising funding for stem cell research to drive market growth196
TABLE 196US: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)197
TABLE 197US: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION)197
TABLE 198US: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)198
TABLE 199US: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)198
TABLE 200US: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)198
TABLE 201US: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)199
TABLE 202US: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION)199
TABLE 203US: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)199
TABLE

Report Title: Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW